There is a document that most companies selling GS-441524 oral capsules would prefer their customers never read.
It was written not by a competitor, not by a regulator, and not by a critic of GS-441524. It was written by Niels C. Pedersen of University of California, Davis — the researcher whose original field studies established GS-441524 as the first effective treatment for FIP, and whose work created the entire market that now exists. He co-authored it alongside Nicole Jacque in November 2021 and published it through the UC Davis Center for Companion Animal Health.
The paper is titled: "Alternative Treatments for Cats with FIP and Natural or Acquired Resistance to GS-441524."
Read that title carefully. The man who gave the world GS-441524 spent 2021 writing a paper about how GS-441524 alone is failing cats — and what needs to come next.
That paper is the scientific foundation behind CureFIP Oral Capsules.
What Dr. Pedersen Actually Found
The paper documents something that the oral GS-441524 market has been quietly aware of but commercially unwilling to address: drug resistance is real, it is confirmed, and it is growing.
Pedersen and Jacque wrote directly:
"Resistance to GS-441524 has been confirmed in a number of cats that have been treated for FIP with GS-441524 in the last 3 years, especially among cats with neurological FIP."
Not suspected. Confirmed. In multiple cats. Over three years. With a particular prevalence in neurological FIP cases where the stakes — and the treatment duration — are highest.
The mechanism is well understood. GS-441524 is what pharmacologists call a non-obligate RNA chain terminator — it stops viral replication by blocking the extension of the virus's RNA strand. This is a highly specific mechanism, which is both its strength and its structural vulnerability. Specific mechanisms create specific targets. And RNA viruses, with their high mutation rates, are exceptionally capable of finding and adapting around specific targets when given enough replication cycles and enough time.
Twelve weeks of daily oral dosing is a lot of time.
Why the "Just Increase the Dose" Approach Doesn't Work
The instinctive commercial response to resistance claims is to add milligrams. More GS-441524. A higher number on the label. Implicit reassurance that if resistance is a risk, your product's higher dose will outrun it.
Pedersen addresses this directly and dismisses it.
He acknowledges that increasing the dose can overcome partial resistance in some cases, but states plainly that:
"Resistance to GS-441524 may be complete or so high that increasing the dose is no longer effective."
At that point, escalating the same compound is not a solution — it is just a more expensive version of the same failure.
He then identifies the two options for genuinely overcoming resistance: higher doses where feasible, or — the superior path —
"using another antiviral that has a different mechanism of resistance, either alone or in combination."
More milligrams of the same thing is not a different mechanism. It is the same mechanism, louder.
What Dr. Pedersen Concluded About Combination Therapy
This is where the paper moves from diagnosis to direction — and where every company still selling pure GS-441524 monotherapy in 2025 has a problem they cannot label their way out of.
Pedersen and Jacque write:
"Combinations of molnupiravir with GC376 or GS-441524 will be used more and more frequently, not only to synergize or complement their individual antiviral effects, but also as a way to prevent drug resistance."
And further:
"Medicinal cocktails have been very effective in preventing drug resistance in HIV/AIDS patients."
This is not hedged speculation. This is a direct statement of clinical direction from the foremost authority in FIP virology, drawing an explicit parallel to HIV — the field where combination antiviral therapy went from theoretical to transformative in a decade, precisely because monotherapy could not solve the resistance problem.
Pedersen was pointing the entire field toward combination therapy in 2021. Most of the companies selling oral GS-441524 today have not followed him there.
The Mechanism Difference That Resistance Cannot Solve
The reason combination therapy works where dose escalation does not is straightforward pharmacology.
GS-441524 and EIDD-1931 — the active metabolite of molnupiravir — attack the FIP virus at two entirely separate points in its lifecycle through two fundamentally different mechanisms:
GS-441524 is a chain terminator. It stops the virus from replicating by preventing the RNA strand from extending. The virus must mutate its RNA polymerase to tolerate this.
EIDD-1931 operates through lethal mutagenesis. It is incorporated into viral RNA during copying and floods the output with genetic errors — not stopping replication, but corrupting it beyond viability. Pedersen's paper notes specifically that EIDD-1931:
"has been shown to function as an RNA mutagen causing several defects in the viral genome"
and that
"its resistance profile will be different"
from GS-441524.
These are not redundant mechanisms. They are independent ones. For the FIP virus to develop resistance against this combination, it would need to simultaneously evolve around chain termination and error induction — two separate adaptive challenges at two separate points in the viral lifecycle. That is not pharmacological wordplay. It is why Pedersen explicitly cites HIV combination therapy as the relevant precedent: HIV became manageable not because scientists found a more powerful single drug, but because they found a second drug that closed the escape route the first one left open.
What CureFIP Oral Capsules Are Built On
CureFIP Oral Capsules combine GS-441524 with EIDD-1931 in a formulation designed around exactly the clinical direction Pedersen mapped. Two mechanisms. Two resistance profiles. Simultaneous pressure on the FIP virus that removes the single-point-of-failure risk that every pure GS-441524 capsule carries.
The milligram count in our capsules is lower than some competitors because it does not need to be higher — it has a second mechanism working alongside it. The synergistic effect of combining two complementary compounds means the combined antiviral pressure exceeds what either compound alone would produce at the same dose. We are not giving you less treatment. We are giving you a different — and better — treatment architecture.
A higher GS-441524 count on a single-compound capsule is a metric that made sense before the resistance question was answered. In 2025, after Pedersen's 2021 paper, after three years of confirmed resistance cases accumulating in the clinical record, it is a metric that tells you only one thing: this formulation was designed around marketing, not pharmacology.
The Question Every Cat Owner Should Now Be Asking
If you are considering oral FIP treatment, there is one question that cuts through every milligram comparison and every price-per-capsule calculation:
Does this formulation have an answer to drug resistance?
Not a higher dose of the same compound. An actual, mechanistically distinct answer.
If the product is pure GS-441524 at any milligram count, it does not. That is not our characterization of the competition. That is the conclusion of the researcher who created GS-441524 treatment, writing under his own name, through his own institution, in 2021.
CureFIP Oral Capsules were built with that conclusion in mind. The cats currently being treated with pure GS-441524 monotherapy deserve formulations that were too.
Pedersen NC, Jacque N. "Alternative Treatments for Cats with FIP and Natural or Acquired Resistance to GS-441524." UC Davis Center for Companion Animal Health, November 3, 2021. Available at: https://ccah.vetmed.ucdavis.edu/sites/g/files/dgvnsk4586/files/inline-files/Approaches-to-drug-resistance-in-cats-treated-with-GS-441524-for-FIP-v3.pdf
CureFIP Oral Capsules are available in multiple strengths. Dosing is determined by body weight and FIP classification. Always follow the treatment protocol provided by your veterinarian or our clinical team.
